Clinical Trial Support
Disease Detection & Characterization
Navigating a drug through a clinical development trajectory is one of the most difficult and expensive challenges that our clients face. At Radiomics.bio we believe that knowledge and understanding are key to success. Our radiomics image analysis provides an array of endpoints for the evaluation and early detection of safety and efficacy of drugs, which are sensitive to the slightest treatment-induced changes. The use of this technology in Phase I and II of drug development allows our clients not only to run shorter trials requiring less patients, but also to be better informed in their decision-making process and in the optimization of the subsequent trial design. Since our radiomics endpoints are based on standard clinical images in DICOM format, they can also be used in a Phase IV setting to demonstrate the real-world efficiency of an approved treatment.
Furthermore, given the possibility to acquire similar scans from animals, Radiomics.bio can accompany its clients during the entire drug development trajectory, starting from preclinical phases up to post-market stages, providing them with true translational tools for an optimized insight-based decision making.
Patient selection & stratification
It is known that not all the patients react the same way to the same treatment; some of them fail to respond to certain therapies, experience adverse events, or develop therapy resistance over time. Radiomics.bio helps its clients to identify the responders’ phenotype and stratify according to the patients' population.
We have previously demonstrated that radiomics-based imaging biomarkers can accurately detect several relevant biological pathways.
This additional information can lead to an optimised patient population selection during pivotal trials, hence increasing the chance on successful market authorisation.
Next to this, we can also assist in the search or development of specific, image-based, pre-screening tools for better patient enrolment.
Prediction of treatment effect
Being able to identify the responder phenotype in a broad population of patients is a first step in going from the traditional “one-size-fits-all” model to a fully personalised-medicine approach.
Radiomics.bio can co-develop companion diagnostic tools to assist clinicians in their patient management and follow-up, strengthening our clients position in value-based reimbursement landscape.